A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT06603571 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of the medications LY3841136 and tirzepatide (LY3298176), alone or together, on weight management in adults who have obesity or are overweight and also have type 2 diabetes.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 350 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-09 · est. completion 2026-08

Where 52 sites · Argentina, United States

What this study is testing ClinicalTrials.gov NCT06603571 ↗

Description as written by the study sponsor.

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Treatments tested

LY3841136 Drug

Administered SC
Tirzepatide Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06603571 ↗